Tourmaline Bio, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Tourmaline Bio's 2024 10-K filing highlights the company's progress in developing pacibekitug for immune and inflammatory diseases, particularly ASCVD and TED, while acknowledging ongoing financial losses and future capital needs.
Tourmaline Bio's 10-K filing highlights the company's focus on developing TOUR006 for autoimmune and cardiovascular diseases, along with financial details and risk factors.